Pasricha PJ, et al. - A randomized trial of the ability of the neurokinin-1 receptor antagonist aprepitant was performed to decrease symptoms in patients with chronic nausea and vomiting because of gastroparesis or gastroparesis-like syndrome. In a randomized trial of patients with chronic nausea and vomiting because of gastroparesis or gastroparesis-like syndrome, aprepitant did not decrease the severity of nausea, when the reduction in VAS score was utilized as the primary outcome. However, aprepitant had varying effects on secondary outcomes of symptom improvement. These outcomes support the need to identify appropriate patient outcomes for trials of therapies for gastroparesis, including potential additional trials for aprepitant.